A new TB vaccine for adolescents and adults, developed by IIT and ILS Bhubaneswar, is set for commercialisation.

India is moving closer to commercialising a new tuberculosis vaccine — the HSP Subunit Vaccine in Adjuvant (DDA). Developed ...

Wealthier consumptive patients had long been directed to salubrious locations such as seaside resorts or spa towns to escape ...

In a significant breakthrough, the Institute of Life Sciences (ILS), Bhubaneswar has developed a next-generation subunit ...

The vaccine triggers strong immune responses against Mycobacterium tuberculosis and is licensed for commercial development to ...

“To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research ...

Pulmonary diseases pose a major health problem worldwide with millions of affected individuals and dire economic impact.

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the ...

IIT Bhubaneswar and ILS transferred novel TB vaccine technology to TechInvention, facilitated by NRDC, to combat tuberculosis ...

The United States endobronchial ultrasound (EBUS) biopsy market is projected to grow from USD 246.82 billion in 2024 to USD ...

The HSP Subunit Vaccine candidate, jointly developed by the Institute of Life Sciences (ILS), Bhubaneswar, and the Indian Institute of Technology (IIT) Bhubaneswar, marks a significant advancement in ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS), along with the ...